The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.
Koen G A M HussaartsFlorine A BergerLisette BinkhorstEsther Oomen-de HoopRoelof W F van LeeuwenRobbert J van AlphenDaniëlle Mathijssen-van SteinNatasja M S de GrootRon H J MathijssenTeun van GelderPublished in: Pharmaceutical research (2019)
Concomitant use of tamoxifen and SRIs resulted in a significantly higher mean QTc-interval, which was especially the case for paroxetine, escitalopram and citalopram. When concomitant administration with an SRI is warranted venlafaxine is preferred.